Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.86 |
| ▸ | HPGD | P15428 | 9/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784271 | 1.00 | GAA (0.86) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL4288972 | 0.93 | GAA (1.00) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL31208320 | 0.90 | GAA (0.76) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL30497269 | 0.89 | GAA (0.70) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL6840229 | 0.88 | GAA (0.72) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL22862457 | 0.86 | GAA (0.66) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL30497313 | 0.84 | GAA (0.75) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL30158973 | 0.82 | GAA (0.61) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL28432074 | 0.80 | GAA (0.70) | GAAHSD17B10HPGDALDH1A1NPC1 | |
| SCHEMBL14723167 | 0.79 | GAA (0.68) | GAAHSD17B10HPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3694840-B1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| CN-101610761-A | 1-amino methyl-L-phenyl-cyclohexane-derivant as the DDP-IV inhibitor | NOVARTIS AG (CH) | 2009-12-23 | — | — | CN | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390610-B2 | Piperazine derivatives as MAGL inhibitors | MAGI3, PYM1, MAG | GAA 1492/4885HSD17B10 4616/4885HPGD 4094/4885 |
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | GAA 86/4885HSD17B10 872/4885HPGD 2114/4885 |
| US-20200299277-A1 | PIPERAZINE DERIVATIVES AS MAGL INHIBITORS | MAGI3, PYM1, MAG | GAA 1492/4885HSD17B10 4616/4885HPGD 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.